Bempedoic Acid CAS 738606-46-7

Comprehensive Guide to Bempedoic Acid (CAS 738606-46-7)

Table of Contents

• 1. Product Overview & Specifications
• 2. Key Applications & Therapeutic Uses
• 3. Clinical Usage Scenarios
• 4. Real-World Case Studies
• 5. Technical Comparison with Alternatives
• 6. Procurement Guidance

1. Product Overview & Specifications

Bempedoic Acid (CAS 738606-46-7) is a first-in-class ATP citrate lyase inhibitor with the following technical parameters:

2. Key Applications & Therapeutic Uses

Primary clinical applications include:

• Treatment of heterozygous familial hypercholesterolemia (HeFH)
• Management of atherosclerotic cardiovascular disease (ASCVD)
• Adjunct therapy to maximally tolerated statins
• Alternative for statin-intolerant patients

3. Clinical Usage Scenarios

3.1 Primary Hyperlipidemia Management

Dosage: 180 mg oral tablet once daily

3.2 Combination Therapy Protocol

Typical combinations with:

• Ezetimibe (dual mechanism therapy)
• PCSK9 inhibitors in high-risk patients

4. Real-World Case Studies

4.1 Cardiovascular Clinic – Boston, USA

Challenge: 62-year-old male with statin-induced myalgia (LDL-C: 145 mg/dL)

Solution: Bempedoic Acid + Ezetimibe combination

Outcome: LDL-C reduced to 78 mg/dL within 12 weeks

4.2 EU Cardiology Center Case

Patient Profile: Post-MI patient with multiple drug intolerances

Regimen: Monotherapy at 180 mg/day

Result: 28% LDL-C reduction sustained over 6 months

5. Technical Comparison with Alternatives

6. Procurement Guidance

For commercial inquiries or technical specifications:

Email: info@vivalr.com
Tel: (86) 15866781826

Why Choose Our Product:

• GMP-certified manufacturing
• Batch-specific COA available
• Customized packaging solutions
• Regulatory support for IND submissions